Statement attributable to:
Gerald E. Harmon, M.D.
President, American Medical Association
January 24 2022
“Given the latest data showing the omicron variant of SARS-CoV-2 is responsible for 99% of current COVID-19 infections, we are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the omicron variant. Limiting the use of these treatments will help ensure patients receive the best available therapy. We encourage physicians to reference the current National Institutes of Health (NIH) COVID-19 treatment guidelines for the latest information on authorized therapies and recommendations for their use.
“We continue to strongly urge every eligible individual to make sure they are up to date on their COVID-19 vaccinations, including booster doses. The Omicron variant is highly contagious and the unvaccinated remain most at risk of severe illness, hospitalization and death if infected. Data further suggests that a booster dose provides greater protection against the omicron variant.”
About the AMA
The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care. The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises, and, driving the future of medicine to tackle the biggest challenges in health care. For more information, visit ama-assn.org.